Thursday, 17th June 2010
In Business In Japan,
Japanese firm launches new drugs
A Japanese pharmaceutical giant has launched three new drugs into the country's market.
Takeda Pharmaceutical Co has launched Unisia to treat hypertension, Vectibix for colon cancer and Nesina for type 2 diabetes.
Nesina is the product of Takeda San Diego, a wholly owned subsidiary of the company.
It is estimated that the three new drugs will drive sales of around 10 billion yen (£1 billion).
Board member Yasuhiko Yamanaka said that the release of Vectibix was part of the companys drive to take a dominant role within the oncology sector.
He added: "Having multiple drugs with different mechanisms of action will allow us to propose treatments that best match the conditions of individual patients."
Takeda has a strong place in the global market for oral diabetes drugs, with two such products in the UK.
It also provides a prostate cancer drug and one for combating malignant bone cancer, which was the first in two decades to get approval from Europe.
Written by Kimberley Homer.